Sun Pharmaceutical Industries Limited (Sun Pharma) announced new data showcasing the efficacy and safety of its dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Notably, LEQSELVI (deuruxolitinib) demonstrated improved hair satisfaction and significant improvement in depression and anxiety for patients with severe alopecia areata. Additional data presented positive results for ILUMYA (tildrakizumab) in moderate-to-severe plaque psoriasis.